HMGCR and osteonecrosis: Upon adjusting for SCGF‐β, the OR of HMGCR inhibitor on osteonecrosis increased from 0.35 (95% CI, 0.19–0.65; p = 8.5 × 10−4) to 0.36 (95% CI, 0.19–0.66; p = 0.001), indicating that a portion of the reduced risk of osteonecrosis associated with HMGCR inhibitor usage could be attributed to an elevated risk in SCGF‐β levels (mediation proportion: 21.3%) (Table S24).